United Therapeutics' first quarter results fell below Wall Street's revenue and earnings expectations, but the market responded favorably. Management attribu...
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the market’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to...
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to $781....
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting results this Wednesday before market hours. Here’s what to look for. United Therape...
Since April 2021, the S&P 500 has delivered a total return of 68.6%. But one standout stock has more than doubled the market - over the past five years, Unit...
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...
In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso (treprostinil) in patients with idiopathic pulmonary fibrosis (IPF) was a resounding success. The news sent shockwaves through the financial markets, propelling
What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 12.7% in the afternoon session after the company announced its TETON-...
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR)
fell 7.2% in the afternoon session after the company reported fourth-quarter financial results that missed revenue expectations, overshadowing an earnings beat.
